IMS Health RWES: The Future of Real-World Insights in Cancer
•
2 likes•1,664 views
The document discusses IMS Health's real-world evidence solutions for cancer, including their cancer data ecosystem. The ecosystem combines various real-world data sources like medical claims, EMR data, and genomic data from over 15 million anonymous cancer patients. It provides comprehensive insights through innovative analytics to help address challenges across the cancer care continuum for clinicians, payers, pharmaceutical companies, patients, and advocacy groups.
Report
Share
More Related Content
What's hot
What's hot (20)
Viewers also liked
Viewers also liked (11)
Similar to IMS Health RWES: The Future of Real-World Insights in Cancer
Similar to IMS Health RWES: The Future of Real-World Insights in Cancer (20)
More from IMSHealthRWES
More from IMSHealthRWES (16)
Recently uploaded
Recently uploaded (20)
IMS Health RWES: The Future of Real-World Insights in Cancer
- 1. REAL-WORLD EVIDENCE SOLUTIONS An RWE ecosystem for commercial and clinical success MEET THE FUTURE OF REAL-WORLD INSIGHTS IN CANCER
- 2. 2 CHALLENGES Cancer and its Complexity Discovering and assessing cancer therapies demands the best insights into disease etiology, treatment, impact, and outcomes. Robust analyses must account for the specific interests of all stakeholders and a variety of issues across the spectrum of cancers. • Clinicians facing highly sophisticated treatment decisions and patient stratification • Payers wanting more proof of value as innovations challenge stretched budgets • Pharma generating more innovative evidence • Patients and caregivers impacting therapeutic options • Increasing role of advocacy groups in awareness building and data generation
- 3. 3www.imshealth.com/rwe HOLISTIC APPROACH IMS RWE Cancer Ecosystem Creating a common foundation of the right oncology real-world data (RWD) to address the cancer-related needs of your entire organization IMS Health combines anonymous patient data with advanced analytics, powerful processing, and deep scientific and commercial expertise to deliver credible, breakthrough oncology insights.
- 4. 4 IMS RWE CANCER ECOSYSTEM Multi-source data representing macro-to-patient-level RWD Comprehensive, Global Cancer Data Innovative and client-centric technology solutions Technology-Enabled Analytics Delivered by a global, dedicated team, including tumor-specific specialists Expertise-Driven Oncology Services Unparalleled Oncology Capabilities
- 5. 5www.imshealth.com/rwe • Comprehensive cross-sectional survey data - Coverage of 25+ primary cancers across 15+ markets - 200,000+ patient histories per year from 4,000+ specialists • IMS MIDAS sales data integration • Primary data collection from specialists and patients • Promotional data • More than 10 years of data from 15+ million anonymous cancer patients - EMR data - Medical claims data - Hospital data - Prescription data - Consumer data - Biomarker and genomic alteration data • Largest, most comprehensive cancer platform commercially available in the USA • EMR extraction capabilities in Europe • Predictive analytics algorithms • Intelligent data interfaces and visualization • Data-linking technologies designed to protect privacy • Disease, patient, and therapy understanding • RD targeting and efficiency • Market access strategies • Real-world value demonstration, including HEOR, pharmacoepidemiology, and drug safety • Commercial positioning, planning, and performance tracking
- 6. 6 UNIQUE APPROACH TO DATA Partnering for Richer Data to Support Precision Therapy • Granular understanding of the comprehensive patient pathway • Insights into differences in unmet needs, treatment use, cost, and outcomes among different genomic subpopulations • Evaluation of targeted therapies, based on unique molecular drivers of individual cancers The IMS Health and Foundation Medicine collaboration enables unique linkage of biomarker data with other sources of RWD such as payer claims and oncology EMR at an anonymous patient level. This provides an unprecedented evidence base for improved medical-scientific and commercialization strategies. Biomarker Duration of Therapy Median Days on Erlotinib Therapy (linked cohort n=152) Source: IMS Health retrospective analysis of IMS RWD Pharmacy Prescription and Medical Claims linked to Foundation Medicine molecular profiling data 107 365 115 312 135 358 EGFR- EGFR+ EGFR+ Exon 20 mut EGFR+ non-Exon 20 mut KRAS+ KRAS-
- 7. 7www.imshealth.com/rwe CUSTOM RWD SOLUTIONS Sourcing and Linking Expertise for T-Shaped Evidence Networks Strategic Data Sourcing • Enhance existing RWD through custom sourcing support to extract data and create custom datasets • Identify and access new data sources addressing specific research needs, also in niche markets • Benefit from IMS RWD Catalogue of 2,200+ data sources globally, including 40%+ in oncology Data Linkage • Understand the full patient pathway through integrating datasets at the record level (e.g., USA and Scandinavia) • Gain deeper insights by sales indication through integration with IMS MIDAS sales data T-Shaped Evidence Networks Broad Deep RangeofDataTypes Population Coverage Nationally relevant databases Augmented datasets Biobank, labs, registries IMS Health T-shaped Evidence Networks address the need to consider both breadth and depth of RWD when accessing the most appropriate fact base
- 8. 8 IMS Health has established excellence in global and local cancer-related research in mature and emerging markets. Proven Approach: We have a track record of successful HTA submissions, published findings, and EMA-accepted Drug Utilization Studies in multiple therapy areas and geographies. Our bibliography comprises more than 3,500 publications, with 520+ in solid and liquid tumors. Quality Systems: Our leading Quality Management System includes electronic control of standards, audit trail, and computer system validation. Credible Solutions: Our databases and methods have been validated in peer-reviewed publications and are used by academics and authorities. They serve as part of a framework for safety assessment and for regulatory purposes. OUR SCIENTIFIC COMMITMENT Bringing Scientific Credibility and Quality to All Our Work
- 9. 9www.imshealth.com/rwe SERVICES Helping Stakeholders All functions can derive value through a shared view of what is happening in real-life healthcare settings. • Launch pricing support • Tumor-specific forecasting • Ongoing value differentiation • Launch/promotion planning • Segmentation and targeting • Cancer patient journeys Commercial • Drug utilization/monitoring • Rigorous and efficient tumor modeling • EMR-enabled outcomes research • Local burden of illness/disease • Adverse event/signal detection • Regulatory submissions and responses HEOR, Pharmacoepidemiology, and Drug Safety • Custom data sourcing • E360TM technology suite • Evidence platforms • T-shaped Cancer Evidence Networks RWE Platform Developers • Translational research • Drug pathways • Target population/product profile • Trial and recruitment feasibility RD
- 10. 10 EVIDENCE PLATFORM IMS RWD Oncology US Platform • More than 10 years of data from 15+ million anonymous cancer patients Our comprehensive cancer data platform links multiple data types, including EMRs, across settings of care. RD Predictive Analytics Tools Medical-Scientific Studies/ Publications HEOR Forecasting KOL Engagement Commercial Patient Analytics Software Application (e.g., E360TM , SAS, R, Tableau) Platform Core Deep Clinical Data (e.g., Genomics Data) Enriched Data (e.g., NLP, Linkage, Local Registry) Broad, Nationally Relevant Databases (e.g., IMS RWD Claims Data) Augmented Datasets (e.g., Oncology EMR) • Data Integration • Data Hosting • Business Rules Analytical Methods • Ongoing Data Governance T-Shaped Portfolio of Data Sources Services Engagement Technology- Enabled Analytics Real-World Data • Geographically representative of the USA to enable a projectable base • Integrates biomarker, histology, consumer, and other patient datasets
- 11. 11www.imshealth.com/rwe HOW WE HELP Enhancing RCT Results with RWE OUR CHALLENGE Help our client determine whether the rate and timing of hemoglobin (Hb) decline in cancer patients receiving chemotherapy seen in pooled RCT was representative of the real world. OUR RESULTS Our analysis verified the RCT findings, increasing payer confidence in those clinical results. This approach can help support future launch strategies when there is uncertainty regarding the applicability of RCT results to real-life settings. OUR SOLUTION We analyzed pooled data from six RCTs and replicated the analysis using our US community oncology clinic EMR database. 440 Patients 5,922 Additional patient experiences analyzed
- 12. IMS Health Real-World Evidence Solutions Uncovering insights from real-world data to improve decision making and patient outcomes ©2016 IMS Health Incorporated and its affiliates. All rights reserved. IMS HEALTH, IMS HEALTH INTELLIGENCE APPLIED and E360 are trademarks of IMS Health Incorporated. IMS RWD Oncology Dynamics The latest addition to the IMS Health cross-sectional survey portfolio CONTACT US FOR MORE INFORMATION The Americas One IMS Drive Plymouth Meeting, PA 19462 USA Tel: +1 484 567 6461 Europe 210 Pentonville Road London, N1 9JY United Kingdom Tel: +44 (0) 20 3075 4800 rweinfo@imshealth.com www.imshealth.com/rwe www.linkedin.com/company/ ims-health-real-world-evidence www.twitter.com/IMSHealthRWE • New global study covering all key tumor types, stages, and lines of therapy • Large physician panel with high patient sample sizes • Facilitates understanding of cancer treatment paradigms • Modern, web-based analytical tool to gain immediate insights NEWIN 2016! IMS HEALTH REAL-WORLD EVIDENCE SOLUTIONS ALK Status Key Cancer: Patient Count NSCLC: Line of Therapy 1st 2nd Awaiting Results Wild Mutant 0 100 200 300 NSCLC COLORECTAL BREAST ALL OTHERS PROSTATE NHL PANCREAS KIDNEY OVARIAN CLL BLADDER CML STOMACH SCLC AML MELANOMA KEY CANCER Count (Patient-ID) Not Tested NSCLC 3rd+ Patient Profile IMS RWD Oncology Dynamics https://websolutions.imshealth.com/EB2/User/CustomerLogin